{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:18:37Z","timestamp":1782562717501,"version":"3.54.5"},"reference-count":51,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011251","name":"Northern Ontario Academic Medicine Association","doi-asserted-by":"publisher","award":["A-21-10"],"award-info":[{"award-number":["A-21-10"]}],"id":[{"id":"10.13039\/100011251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,2]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate how urine drug screening (UDS) frequency is associated with retention in opioid agonist treatment (OAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data for this retrospective cohort study of 55 921 adults in OAT in Ontario, Canada, were derived from administrative sources between 1 January 2011 and 31 December 2015. All patient information was linked anonymously across databases using encrypted health card numbers. Descriptive statistics were calculated for comparing UDS frequency groups using standardised differences (d) where d less than 10% indicated a statistically significant difference. A logistic regression model was then used to calculate ORs adjusting for baseline covariates, including sex, age, location of residence, income quintile, mental disorders, HIV status and deep tissue infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 70% of the cohort had four or more UDS tests per month (weekly or more UDS). Significant associations were observed between UDS frequency and 1-year treatment retention in OAT biweekly (adjusted OR (aOR)=3.20, 95% CI 2.75 to 3.75); weekly UDS (aOR=6.86, 95% CI 5.88 to 8.00) and more than weekly (aOR=8.03, 95% CI 6.87 to 9.38) using the monthly or less groups as the reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified an association between weekly UDS and 1-year treatment retention in OAT. There is an active discussion within Canada about the utility of UDS. The lack of evidence for the impact of UDS on retention has left it open to some to argue they simply provide a barrier to patient engagement. Therefore, it is timely of this study to demonstrate that more frequent urine testing is not associated with a reduction in treatment retention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-060857","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T11:25:44Z","timestamp":1665573944000},"page":"e060857","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study"],"prefix":"10.1136","volume":"12","author":[{"given":"Kristen A","family":"Morin","sequence":"first","affiliation":[{"name":"ICES North, Sudbury, Ontario, Canada"},{"name":"Health Sciences North Research Institute, Sudbury, Ontario, Canada"},{"name":"Northern Ontario School of Medicine-East Campus, Sudbury, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Dabous","sequence":"additional","affiliation":[{"name":"Northern Ontario School of Medicine-East Campus, Sudbury, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vojtesek","sequence":"additional","affiliation":[{"name":"Northern Ontario School of Medicine-East Campus, Sudbury, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8769-1785","authenticated-orcid":false,"given":"David","family":"Marsh","sequence":"additional","affiliation":[{"name":"ICES North, Sudbury, Ontario, Canada"},{"name":"Northern Ontario School of Medicine-East Campus, Sudbury, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"2025121410025435000_12.10.e060857.1","unstructured":"Ontario PH , Tool IO . Opioid-related mortality and morbidity in Ontario Toronto, 2021. Available: https:\/\/www.publichealthontario.ca\/en\/data-and-analysis\/substance-use\/interactive-opioid-tool#\/trends"},{"key":"2025121410025435000_12.10.e060857.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m772"},{"key":"2025121410025435000_12.10.e060857.3","unstructured":"Surveillance of Opioid- and Stimulant-Related Harms in Canada. Public agency of Canada. apparent opioid and stimulant toxicity deaths 2021 Ottawa, Canada"},{"key":"2025121410025435000_12.10.e060857.4","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses . Opioid and Stimulant-related harms in Canada, 2020"},{"key":"2025121410025435000_12.10.e060857.5","unstructured":"Government of Canada . Opioid-related harms in Canada, 2020. Available: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids\/"},{"key":"2025121410025435000_12.10.e060857.6","doi-asserted-by":"crossref","unstructured":"Ball CRA . The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.","DOI":"10.1007\/978-1-4613-9089-3"},{"key":"2025121410025435000_12.10.e060857.7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2025121410025435000_12.10.e060857.8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-Effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025121410025435000_12.10.e060857.9","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1111\/add.15574","article-title":"Impact of treatment duration on mortality among veterans with opioid use disorder in the United States Veterans health administration","volume":"116","author":"Ching","year":"2021","journal-title":"Addiction"},{"key":"2025121410025435000_12.10.e060857.10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","article-title":"Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy","volume":"64","author":"McEachern","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2025121410025435000_12.10.e060857.11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9479612.x"},{"key":"2025121410025435000_12.10.e060857.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025121410025435000_12.10.e060857.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.05.001"},{"key":"2025121410025435000_12.10.e060857.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00179.x"},{"key":"2025121410025435000_12.10.e060857.15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10550880802324382","article-title":"One-Year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel","volume":"27","author":"Peles","year":"2008","journal-title":"J Addict Dis"},{"key":"2025121410025435000_12.10.e060857.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108031","article-title":"One year of methadone maintenance treatment in a fentanyl endemic area: safety, repeated exposure, retention, and remission","volume":"115","author":"Stone","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2025121410025435000_12.10.e060857.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00438.x"},{"key":"2025121410025435000_12.10.e060857.18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3109\/10826084.2015.1135953","article-title":"Clinical and public health considerations in urine drug testing to identify and treat substance use","volume":"51","author":"Barthwell","year":"2016","journal-title":"Subst Use Misuse"},{"key":"2025121410025435000_12.10.e060857.19","unstructured":"British Columbia Centre on Substance Use & CIHR Canadian Research Initiative on Substance Misuse . A guideline for the management of opioid use disorder, 2017"},{"key":"2025121410025435000_12.10.e060857.20","unstructured":"Ministry of Health and Long Term Care . Opioid agonist maintenance program (OAMP) monthly management fee and point of care drug testing health services branch, 2012. Available: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/bulletins\/4000\/bul4548.pdf"},{"key":"2025121410025435000_12.10.e060857.21","unstructured":"Centre for Addiction and Mental Health . Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder; 2021."},{"key":"2025121410025435000_12.10.e060857.22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/CXA.0000000000000015","article-title":"Large variation in provincial guidelines for urine drug screening during opioid agonist treatment in Canada","volume":"9","author":"Moss","year":"2018","journal-title":"Can J Addict"},{"key":"2025121410025435000_12.10.e060857.23","unstructured":"ICES Data Dictionary Toronto Ontario , 2016. Available: https:\/\/datadictionary.ices.on.ca\/Applications\/DataDictionary\/Default.aspx"},{"key":"2025121410025435000_12.10.e060857.24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.4.481"},{"key":"2025121410025435000_12.10.e060857.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.907295"},{"key":"2025121410025435000_12.10.e060857.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2942"},{"key":"2025121410025435000_12.10.e060857.27","first-page":"344","article-title":"[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]","volume":"82","author":"von Elm","year":"2008","journal-title":"Rev Esp Salud Publica"},{"key":"2025121410025435000_12.10.e060857.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01310.x"},{"key":"2025121410025435000_12.10.e060857.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.010"},{"key":"2025121410025435000_12.10.e060857.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.013"},{"key":"2025121410025435000_12.10.e060857.31","unstructured":"Volkow ND . America\u2019s Addiction to Opioids: Heroin and Prescription Drug Abuse. Available: https:\/\/www.nih.gov\/sites\/default\/files\/institutes\/olpa\/20140514-senate-testimony-volkow.pdf"},{"key":"2025121410025435000_12.10.e060857.32","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp186"},{"key":"2025121410025435000_12.10.e060857.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.008"},{"key":"2025121410025435000_12.10.e060857.34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"2025121410025435000_12.10.e060857.35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","article-title":"Evaluating the effectiveness of first-time methadone maintenance therapy across Northern, rural, and urban regions of Ontario, Canada","volume":"9","author":"Eibl","year":"2015","journal-title":"J Addict Med"},{"key":"2025121410025435000_12.10.e060857.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-017-0134-5","article-title":"The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in northern and rural Ontario","volume":"14","author":"Franklyn","year":"2017","journal-title":"Harm Reduct J"},{"key":"2025121410025435000_12.10.e060857.37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1303"},{"key":"2025121410025435000_12.10.e060857.38","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"2025121410025435000_12.10.e060857.39","unstructured":"Sas version 9.4 Cary, North Carolina, 2020. Available: https:\/\/www.sas.com\/en_us\/software\/sas9.html"},{"key":"2025121410025435000_12.10.e060857.40","unstructured":"Franklyn MAE , N.E JKLightfoot , Marsh DC . Journal of Addiction Medicine and Therapy. In: Geography, treatment modality, and substance use: evaluating factors that impact opioid agonist therapy in northern Ontario. Canada, 2016."},{"key":"2025121410025435000_12.10.e060857.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00160-5"},{"key":"2025121410025435000_12.10.e060857.42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies","volume":"74","author":"Priest","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2025121410025435000_12.10.e060857.43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10550880802122620","article-title":"The impact of benzodiazepine use on methadone maintenance treatment outcomes","volume":"27","author":"Brands","year":"2008","journal-title":"J Addict Dis"},{"key":"2025121410025435000_12.10.e060857.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187633","article-title":"The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada","volume":"12","author":"Franklyn","year":"2017","journal-title":"PLoS One"},{"key":"2025121410025435000_12.10.e060857.45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1017\/S1092852900021490","article-title":"Opioids: from physical pain to the pain of social isolation","volume":"12","author":"Stein","year":"2007","journal-title":"CNS Spectr"},{"key":"2025121410025435000_12.10.e060857.46","first-page":"702","article-title":"Psychosocial factors associated with relapse in men with alcohol or opioid dependence","volume":"130","author":"Mattoo","year":"2009","journal-title":"Indian J Med Res"},{"key":"2025121410025435000_12.10.e060857.47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/070674377401900108","article-title":"Social and psychological characteristics of heroin addicts dropping out of methadone treatment","volume":"19","author":"Krakowski","year":"1974","journal-title":"Can Psychiatr Assoc J"},{"key":"2025121410025435000_12.10.e060857.48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drugalcdep.2017.07.007","article-title":"Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder","volume":"179","author":"Stein","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"2025121410025435000_12.10.e060857.49","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(93)90052-R"},{"key":"2025121410025435000_12.10.e060857.50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1000"},{"key":"2025121410025435000_12.10.e060857.51","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamainternmed.2021.4109","article-title":"Reassessing the role of routine urine drug screening in opioid use disorder treatment","volume":"181","author":"Incze","year":"2021","journal-title":"JAMA Intern Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-060857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:03:06Z","timestamp":1765735386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-060857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2022-060857"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-060857","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}